Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 10, 2015, Pages E1135-E1142

  Pasettoa, Matteo ^a,c   Antignani, Antonella ^a   Ormanoglub, Pinar ^b   Buehlerb, Eugen ^b   Guhab, Rajarshi ^b   Pastana, Ira ^a   Martinb, Scott E ^b   FitzGeralda, David J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GB Rossi Hospital   (Italy)

Author keywords

Genome; Immunotoxin; RNAi; Screen; Toxin

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 1; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 4; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 5; ADENOSINE TRIPHOSPHATE; DIPHTHERIA TOXIN; FURIN; IMMUNOTOXIN; IMMUNOTOXIN SS1P; KDEL RECEPTOR 2; MESOTHELIN; RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; ESSENTIAL GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; GENOME; GOLGI COMPLEX; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RNA INTERFERENCE; SENSITIZATION; WESTERN BLOTTING; ANIMAL; METABOLISM;

PSEUDOMONAS EXOTOXIN;

ANIMALS; ENDOPLASMIC RETICULUM; GOLGI APPARATUS; HUMANS; IMMUNOTOXINS; RNA INTERFERENCE;

EID: 84924353446     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1501958112     Document Type: Article

References (69)

1. Palanca-Wessels MC, Press OW (2014) Advances in the treatment of hematologic malignancies using immunoconjugates. Blood 123(15):2293-2301.
2. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5):317-327.
3. Sievers EL, Senter PD (2013) Antibody-drug conjugates in cancer therapy. Annu Rev Med 64:15-29.
4. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I (2011) Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 71(20): 6300-6309.
5. Du X, Beers R, Fitzgerald DJ, Pastan I (2008) Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 68(15):6300-6305.
6. Sutherland MS, et al. (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281(15):10540-10547.
7. Weldon JE, et al. (2009) A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 113(16):3792-3800.
8. Weidle UH, et al. (2014) Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genomics Proteomics 11(1):25-38.
9. Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I (2014) Immunotoxins for leukemia. Blood 123(16):2470-2477.
10. Weldon JE, Pastan I (2011) A guide to taming a toxin-Recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 278(23):4683-4700.
11. Chiron MF, Fryling CM, FitzGerald D (1997) Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J Biol Chem 272(50):31707-31711.
12. Chiron MF, Fryling CM, FitzGerald DJ (1994) Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem 269(27): 18167-18176.
13. McKee ML, FitzGerald DJ (1999) Reduction of furin-nicked Pseudomonas exotoxin A: An unfolding story. Biochemistry 38(50):16507-16513.
14. Chaudhary VK, Jinno Y, FitzGerald D, Pastan I (1990) Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci USA 87(1):308-312.
15. Kreitman RJ, Pastan I (1995) Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 307(Pt 1):29-37.
16. Uthman S, et al. (2013) The amidation step of diphthamide biosynthesis in yeast requires DPH6, a gene identified through mining the DPH1-DPH5 interaction network. PLoS Genet 9(2):e1003334.
17. Abdel-Fattah W, Scheidt V, Uthman S, Stark MJ, Schaffrath R (2013) Insights into diphthamide, key diphtheria toxin effector. Toxins (Basel) 5(5):958-968.
18. Zhang Y, et al. (2010) Diphthamide biosynthesis requires an organic radical generated by an iron-sulphur enzyme. Nature 465(7300):891-896.
19. Gupta PK, Liu S, Leppla SH (2010) Characterization of a Chinese hamster ovary cell mutant having a mutation in elongation factor-2. PLoS ONE 5(2):e9078.
20. Antignani A, Fitzgerald D (2013) Immunotoxins: The role of the toxin. Toxins (Basel) 5(8):1486-1502.
21. Wei H, et al. (2012) Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc Natl Acad Sci USA 109(18):6898-6903.
22. Wei H, et al. (2013) A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene. J Biol Chem 288(17): 12305-12312.
23. Moreau D, et al. (2011) Genome-wide RNAi screens identify genes required for Ricin and PE intoxications. Dev Cell 21(2):231-244.
24. Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10(2):130-137.
25. Dar AC, Das TK, Shokat KM, Cagan RL (2012) Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486(7401):80-84.
26. Chang K, Pai LH, Batra JK, Pastan I, Willingham MC (1992) Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 52(1):181-186.
27. Hassan R, Bera T, Pastan I (2004) Mesothelin: A new target for immunotherapy. Clin Cancer Res 10(12 Pt 1):3937-3942.
28. Hassan R, Kreitman RJ, Pastan I, Willingham MC (2005) Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 13(3):243-247.
29. Ho M, et al. (2007) Mesothelin expression in human lung cancer. Clin Cancer Res 13(5): 1571-1575.
30. Argani P, et al. (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7(12):3862-3868.
31. Iacobuzio-Donahue CA, et al. (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: A comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63(24): 8614-8622.
32. Hassan R, et al. (2014) Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 120(21):3311-3319.
33. Martin SE, et al. (2007) Multiplexing siRNAs to compress RNAi-based screen size in human cells. Nucleic Acids Res 35(8):e57.
34. König R, et al. (2007) A probability-based approach for the analysis of large-scale RNAi screens. Nat Methods 4(10):847-849.
35. Marine S, Bahl A, Ferrer M, Buehler E (2012) Common seed analysis to identify offtarget effects in siRNA screens. J Biomol Screen 17(3):370-378.
36. Jensen LJ, et al. (2009) STRING 8-A global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37(Database issue):D412-D416.
37. Popoff V, et al. (2011) Several ADP-ribosylation factor (Arf) isoforms support COPI vesicle formation. J Biol Chem 286(41):35634-35642.
38. Claude A, et al. (1999) GBF1: A novel Golgi-associated BFA-resistant guanine nucleotide exchange factor that displays specificity for ADP-ribosylation factor 5. J Cell Biol 146(1):71-84.
39. Monetta P, Slavin I, Romero N, Alvarez C (2007) Rab1b interacts with GBF1 and modulates both ARF1 dynamics and COPI association. Mol Biol Cell 18(7):2400-2410.
40. Reiling JH, et al. (2013) A CREB3-ARF4 signalling pathway mediates the response to Golgi stress and susceptibility to pathogens. Nat Cell Biol 15(12):1473-1485.
41. Hazes B, Read RJ (1997) Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry 36(37):11051-11054.
42. Wang Q, Li L, Ye Y (2008) Inhibition of p97-dependent protein degradation by Eeyarestatin I. J Biol Chem 283(12):7445-7454.
43. Wang Q, et al. (2010) The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. PLoS ONE 5(11): e15479.
44. Cross BC, et al. (2009) Eeyarestatin I inhibits Sec61-mediated protein translocation at the endoplasmic reticulum. J Cell Sci 122(Pt 23):4393-4400.
45. Pehar M, Jonas MC, Hare TM, Puglielli L (2012) SLC33A1/AT-1 protein regulates the induction of autophagy downstream of IRE1/XBP1 pathway. J Biol Chem 287(35): 29921-29930.
46. Yamaizumi M, Mekada E, Uchida T, Okada Y (1978) One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15(1):245-250.
47. Bushman FD, et al. (2009) Host cell factors in HIV replication: meta-analysis of ge-nome-wide studies. PLoS Pathog 5(5):e1000437.
48. Sigoillot FD, King RW (2011) Vigilance and validation: Keys to success in RNAi screening. ACS Chem Biol 6(1):47-60.
49. Gilbert LA, et al. (2014) Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159(3):647-661.
50. Wernick NL, Chinnapen DJ, Cho JA, Lencer WI (2010) Cholera toxin: An intracellular journey into the cytosol by way of the endoplasmic reticulum. Toxins (Basel) 2(3):310-325.
51. Li S, Spooner RA, Hampton RY, Lord JM, Roberts LM (2012) Cytosolic entry of Shigalike toxin a chain from the yeast endoplasmic reticulum requires catalytically active Hrd1p. PLoS ONE 7(7):e41119.
52. Słomińska-Wojewódzka M, et al. (2014) The role of EDEM2 compared with EDEM1 in ricin transport from the endoplasmic reticulum to the cytosol. Biochem J 457(3):485-496.
53. Eshraghi A, et al. (2014) Cytolethal distending toxins require components of the ER-associated degradation pathway for host cell entry. PLoS Pathog 10(7):e1004295.
54. Aletrari M-O, et al. (2011) Eeyarestatin 1 interferes with both retrograde and anterograde intracellular trafficking pathways. PLoS ONE 6(7):e22713.
55. Kim TH, Leslie P, Zhang Y (2014) Ribosomal proteins as unrevealed caretakers for cellular stress and genomic instability. Oncotarget 5(4):860-871.
56. Wilson-Edell KA, et al. (2014) RPL24: A potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth. Oncotarget 5(13): 5165-5176.
57. Dave B, et al. (2014) Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proc Natl Acad Sci USA 111(24):8838-8843.
58. Yau C, et al. (2010) A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 12(5):R85.
59. Song MJ, et al. (2011) RPL36 as a prognostic marker in hepatocellular carcinoma. Pathol Int 61(11):638-644.
60. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK (2002) Expression profile of differen-tially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 23(6):967-975.
61. Lau TP, et al. (2014) Pair-wise comparison analysis of differential expression of mRNAs in early and advanced stage primary colorectal adenocarcinomas. BMJ Open 4(8): e004930.
62. Aspesi A, et al. (2014) Dissecting the transcriptional phenotype of ribosomal protein deficiency: Implications for Diamond-Blackfan Anemia. Gene 545(2):282-289.
63. Peng Y, et al. (2014) Deficient import of acetyl-CoA into the ER lumen causes neurodegeneration and propensity to infections, inflammation, and cancer. J Neurosci 34(20):6772-6789.
64. Narla A, et al. (2014) L-Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q-syndrome in a TP53-independent way. Br J Haematol 167(4): 524-528.
65. Bourgoin SG, El Azreq M-A (2012) Small inhibitors of ADP-ribosylation factor activation and function in mammalian cells. World J Pharmacol 1:55-64.
66. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11(2):117-126.
67. Pastan I, Beers R, Bera TK (2004) Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 248:503-518.
68. Ogata M, Pastan I, FitzGerald D (1991) Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes. Infect Immun 59(1):407-414.
69. Aalto AP, Poranen MM, Grimes JM, Stuart DI, Bamford DH (2010) In vitro activities of the multifunctional RNA silencing polymerase QDE-1 of Neurospora crassa. J Biol Chem 285(38):29367-29374.